BioPharma

07 October, 2026 | Wednesday | News

Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand Identity

Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma")...

Lab

21 September, 2026 | Monday | News

OGT Expands SureSeq NGS Indexing Capacity to 384 Samples per Run

OGT, a leading global provider of genomic research and diagnostic solutions, announced the expansion of its SureSeq™ Universal NGS Unique Dual Index (UDI) range, enabling laboratories to multiplex up to 3...

BioTech

02 October, 2026 | Friday | Analysis

Biotech Failures 2026: What Did Not Happen in APAC Biopharma

Approvals get counted, deals get ranked, listings get priced. The other half of the year, the programmes that stopped, the applications that came back, the partnerships that ended quietly in a footnote, rarely ...

Contract Services

05 October, 2026 | Monday | News

Lonza and Asimov Partner to Advance Lentiviral Vector Manufacturing for In Vivo Therapies

Collaboration connects Asimov’s genetic design and cell line technologies with Lonza’s process development, scale-up and GMP manufacturing expertise. Integrated approach brings manufactur...

Consumer Health

06 October, 2026 | Tuesday | News

FDA Expands Lilly’s Jaypirca Approval to First-Line CLL/SLL Treatment

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent B...

Medtech

02 October, 2026 | Friday | News

AsiaMedic Becomes First in ASEAN to Adopt GE HealthCare’s MR31 MRI Platform

Singapore imaging provider is the earliest site in the region to adopt a new generation of MRI technology. MR31 will enable AsiaMedic to reduce scan times and widen the range of complex examinations availabl...

Cell & Gene

07 October, 2026 | Wednesday | Analysis

Every CAR-T Therapy Approved in Asia-Pacific, and What It Costs

Method in brief What counts. A CAR-T cell therapy approved on one of seven national registers: China's NMPA, Japan's PMDA and MHLW, Korea's MFDS, Taiwan's TFDA, Singapore's HSA, Australia's TGA and Ind...


Biopharma APAC Infomercial

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close